FOXO3 and infection: The siRNA treatments kept FoxO protein levels below those seen in NT control-treated infections; quantification of secondary antibody fluorophore signals for detection of FoxO1 and FoxO3a at 120 hpi in the siRNA treatment settings indicated that the siRNA treatments reduced their expression by 60% relative to that at the equivalent time point in the NT control setting (Fig. 4D and E; Fig. S3).